Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. American Thoracic Society. News Release: New Tuberculosis Blood Test Spots Hidden Infection. Available at http://www.washingtonpost.com/wp-dyn/content/article/2007/03/15/AR2007031500939.html. Last accessed September 12, 2025.
2. World Health Organization. Drug-Resistant Tuberculosis. Available at https://www.who.int/news/item/13-01-2012-drug-resistant-tuberculosis. Last accessed September 12, 2025.
3. Kim L, Moonan PK, Yelk Woodruff RS, Kammerer JS, Haddad MB. Epidemiology of recurrent tuberculosis in the United States, 1993–2010. Int J Tuberc Lung Dis. 2013;17(3):357-360.
4. Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis—United States, 1993–2006. MMWR. 2007;56(11):250-253.
5. Centers for Disease Control and Prevention. About Drug-Resistant Tuberculosis Disease. Available at https://www.cdc.gov/tb/about/drug-resistant.html. Last accessed September 12, 2025.
6. Centers for Disease Control and Prevention. Clinical Testing Guidance for Tuberculosis: Interferon Gamma Release Assay. Available at https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html. Last accessed September 12, 2025.
8. Centers for Disease Control and Prevention. Clinical Overview of Drug-Resistant Tuberculosis Disease. Available at https://www.cdc.gov/tb/hcp/clinical-overview/drug-resistant-tuberculosis-disease.html. Last accessed September 12, 2025.
9. Congress. The XDR Tuberculosis Incident: A Poorly Coordinated Federal Response to an Incident with Homeland Security Implications. Available at https://www.govinfo.gov/content/pkg/CHRG-110hhrg48919/html/CHRG-110hhrg48919.htm. Last accessed September 12, 2025.
10. Centers for Disease Control and Prevention. CDC WONDER: OTIS TB Data 1993–2020 Request. Available at https://wonder.cdc.gov/tb-v2020.html. Last accessed September 12, 2025.
12. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med. 1999;340(5):359-366.
13. Centers for Disease Control and Prevention. Trends in tuberculosis incidence—United States, 2006. MMWR. 2007;56:245-250.
14. World Health Organization. Tuberculosis. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Last accessed September 12, 2025.
16. Centers for Disease Control and Prevention. Update on CDC Investigation into People Potentially Exposed to Patient with Extensively Drug-Resistant TB. Press Conference Transcript. Available at https://biotech.law.lsu.edu/cphl/Practice/tb/xdr-03.htm. Last accessed September 12, 2025.
17. Simpkins S, Hench C. "Super bugs:" emerging pathogens and multidrug-resistant organisms. NURSEweek. 1996;8(13):8-9.
18. Cameron LH, Starke JR. Tuberculosis (Mycobacterium tuberculosis). In: Kliegman RM, St. Geme JW III, Blum NJ, Tasker RC, Wilson KM, Schuh AM, Mack CL (eds). Nelson Textbook of Pediatrics. 22nd ed. Philadelphia, PA: WB Saunders Co.; 2024: 1835-1855.
19. Hersh L, Salzman B, Snyderman D. Health literacy in primary care practice. Am Fam Physician. 2015;92(2):118-124.
20. Centers for Disease Control and Prevention. TB Risk and People Born in or Who Travel to Places Where TB is Common. Available at https://www.cdc.gov/tb/risk-factors/country.html. Last accessed September 12, 2025.
21. Wang S, Carruthers B, Turner J. The influence of increasing age on susceptibility of the elderly to tuberculosis. Open Longev Sci. 2012;6:73-82.
22. Raviglione MC, Gori A. Tuberculosis. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, Holland SM, Langford CA (eds). Harrison's Principles of Internal Medicine. 22nd ed. New York, NY: McGraw-Hill; 2025.
23. Centers for Disease Control and Prevention. Provisional 2024 Tuberculosis Data, United States. Available at https://www.cdc.gov/tb-data/2024-provisional/index.html. Last accessed September 12, 2025.
24. Deutsch-Feldman M, Pratt RH, Price SF, Tsang CA, Self JL. Tuberculosis—United States, 2020. MMWR. 2021;70:409-414.
25. Centers for Disease Control and Prevention. Slide Set: Epidemiology of Pediatric Tuberculosis in the United States, 1993–2017. Available at https://stacks.cdc.gov/view/cdc/81582/cdc_81582_DS2.pdf. Last accessed September 12, 2025.
26. Soini H, Musser JM. Molecular diagnosis of mycobacteria. Clinical Chemistry. 2001;47(5):809-814.
27. Cantwell MF, Shehab ZM, Costello AM, et al. Congenital tuberculosis. N Engl J Med. 1994;330(15):1051-1054.
28. National Commission on Correctional Health Care. TB patient in compulsory detention. Correct Care. 2007;21(1):9.
29. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA. 2000;283(15):2003-2007.
30. Saukkonen JJ, Duarte R, Munsiff SS, et al. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2025;211:15-33.
31. Snider GL. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med. 1997;126(3):237-243.
33. York N. Management of clients with parenchymal and pleural disorders. In: Black JM, Hawks JH (eds). Medical-Surgical Nursing: Clinical Management for Positive Outcomes. 8th ed. Philadelphia, PA: WB Saunders Co.; 2008: 1597-1634.
34. Centers for Disease Control and Prevention. Core Curriculum on Tuberculosis: What the Clinician Should Know. Available at https://www.cdc.gov/tb/hcp/education/core-curriculum-on-tuberculosis.html. Last accessed September 12, 2025.
35. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR. 2005;54(RR17);1-141.
36. Alexander KA, Laver PN, Michel AL, et al. Novel Mycobacterium tuberculosis complex pathogen, M. mungi. Emerg Infect Dis. 2010;16(8):1296-1299.
37. Cousins DV, Bastida R, Cataldi A, et al. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. Int J Syst Evol Microbiol. 2003;53:1305-1314.
38. van Soolingen D, Hoogenboezem T, de Haas PEW, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol. 1997;47(4):1236-1245.
39. Aranaz A, Pavlik I, Niemann S, et al. Characterization of Mycobacterium caprae isolates from Europe by mycobacterial interspersed repetitive unit genotyping. J Clin Microbiol. 2005;43(10):4984-4992.
40. Centers for Disease Control and Prevention. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR. 1997;46(RR15):1-10.
41. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(RR15):49-55.
42. LexiDrug. Available at https://online.lexi.com. Last accessed September 12, 2025.
43. Tran JH, Montakantikul P. The safety of antituberulosis medications during breastfeeding. J Hum Lact. 1998;14(4):337-340.
44. Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis. 2008;198(10):1491-1501.
45. Breen RAM, Barry SM, Smith CJ, et al. The clinical application of a rapid lung-oriented TB immunoassay in individuals with possible tuberculosis. Thorax. 2008;63:67-71.
46. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:111-115.
47. Reither K, Saathoff E, Jung J, et al. Evaluation of Diagnos TB AG, a flow-through immunoassay for rapid detection of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(2):238-240.
48. Centers for Disease Control and Prevention. Clinical Testing Guidance for Tuberculosis: Interferon Gamma Release Assay. Available at https://www.cdc.gov/tb/hcp/testing-diagnosis/interferon-gamma-release-assay.html. Last accessed September 12, 2025.
49. U.S. Food and Drug Administration. Medical Devices: T-Spot.TB-P070006. Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?ID=320334. Last accessed September 12, 2025.
50. Van Crevel R, Hill RC. Tuberculosis. In: Cohen J, Powderly WG, Opal SM (eds). Infectious Diseases. New York, NY: Elsevier; 2016: 271-284.
51. Centers for Disease Control and Prevention. Testing for Tuberculosis. Available at https://www.cdc.gov/tb/testing. Last accessed September 12, 2025.
52. Centers for Disease Control and Prevention. Treatment for Latent Tuberculosis Infection. Available at https://www.cdc.gov/tb/hcp/treatment/latent-tuberculosis-infection.html. Last accessed September 12, 2025.
53. U.S. Food and Drug Administration. FDA Approved First Drug to Treat Multi-Drug Resistant Tuberculosis. Available at https://wayback.archive-it.org/7993/20170112023916/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm. Last accessed September 12, 2025.
55. Centers for Disease Control and Prevention. Xpert MTB/RIF Assay. Available at https://www.cdc.gov/tb/php/laboratory-information/xpert-mtb-rif-assay.html. Last accessed September 12, 2025.
56. Parsons SD, Drewe JA, Gey van Pittius NC, Warren RM, van Helden PD. Novel cause of tuberculosis in meerkats, South Africa. Emerg Infect Dis. 2013;19(12):2004-2007.
57. Centers for Disease Control and Prevention. Treatment for Latent TB Infection. Available at https://www.cdc.gov/tb/hcp/treatment/latent-tuberculosis-infection.html. Last accessed September 12, 2025.
58. Centers for Disease Control and Prevention. Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States. Available at https://findtbresources.cdc.gov/view?id=298378. Last accessed September 12, 2025.
59. USAID. The National Action Plan for Combating Multidrug-Resistant Tuberculosis. Available at https://www.hhs.gov/sites/default/files/national-action-plan-for-combating-multidrug-resistant-tuberculosis.pdf. Last accessed September 12, 2025.
60. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR. 2013;62(RR9):1-12.
61. Centers for Disease Control and Prevention. Treatment for Drug-Resistant Tuberculosis Disease. Available at https://www.cdc.gov/tb/hcp/treatment/drug-resistant-tuberculosis-disease.html. Last accessed September 12, 2025.
62. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR. 2003;52(RR11):1-77.
63. Los Angeles County Department of Public Health. California TB Screening Mandates by Groups and Occupations. Available at http://publichealth.lacounty.gov/tb/docs/TBScreeningMandatesSchools.pdf. Last accessed September 12, 2025.
64. U.S. Food and Drug Administration. FDA Approves New Drug for Treatment-Resistant Forms of Tuberculosis that Affects the Lungs. Available at https://web.archive.org/web/20250520152621/https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs. Last accessed September 12, 2025.
65. Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR. 2018;67:723-726.
66. Schmitz DM, Fleissner D, Tran A. Impact of pharmacist-delivered patient education on tuberculosis drug therapy adherence. Advances in Pharmacy. 2017;1(1):Article 3.
67. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147.
68. World Health Organization. Q&A: Investigational Vaccine Candidate M72/AS01E. Available at https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-investigational-vaccine-candidate-m72-as01e. Last accessed September 12, 2025.
69. Tait DR MB, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429-2439.
70. Williams PM, Pratt RH, Walker WL, Price SF, Stewart RJ, Feng PI. Tuberculosis—United States, 2023. MMWR. 2024;73(12):265-270.
71. Commonwealth of Massachusetts. Nucleic Acid Amplification Testing for Early Diagnosis of Tuberculosis and Identification of Rifampin Resistance. Available at https://www.mass.gov/service-details/nucleic-acid-amplification-testing-for-early-diagnosis-of-tuberculosis-and-identification-of-rifampin-resistance. Last accessed September 12, 2025.
72. Cepheid. Xpert MTB/XDR. Available at https://www.cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-XDR. Last accessed September 12, 2025.
73. Merck Manual. Cerebrospinal Fluid Findings in Meningitis. Available at https://www.merckmanuals.com/professional/multimedia/table/csf-findings-in-meningitis. Last accessed September 12, 2025.
74. Centers for Disease Control and Prevention. Provisional CDC Guidance for the Use of Pretomanid as Part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease. Available at https://archive.cdc.gov/#/details?url=https://www.cdc.gov/tb/hcp/treatment/bpal.html. Last accessed August 31, 2022.
75. Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis—United States, 2022. MMWR. 2022;71:285-289.
76. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. 2020;69(1):1-11.
77. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387:810-823.
78. Centers for Disease Control and Prevention. Tuberculosis (TB): Clinical Overview of Tuberculosis. Available at https://www.cdc.gov/tb/hcp/clinical-overview/index.html. Last accessed September 12, 2025.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.